Mirati gauging sale interest of Big Pharmas — report

Mirati Therapeutics, maker of the experimental cancer drug adagrasib, is piquing the interest of Big Pharmas, according to a report from Bloomberg.

On Tuesday, the biotech’s stock $MRTX rose by almost 16%, jumping from just under $75 to over $86. After Wednesday’s opening bell, Mirati’s stock continued to climb nearly $3 apiece. But that still leaves it down 43% from the beginning of this year, a reflection of the biotech market as a whole.

According to the report, Mirati is working with an advisor, but no formal bids have been placed by Big Pharma companies yet, and more data from a combination study with Keytruda could be key to the progression of talks. Mirati did not respond to a request for comment as of publication time.

The biggest of names in pharma could be interested, Jefferies analysts noted, including those without KRAS…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.